65,437 trials
Excessive Daytime Sleepiness · Narcolepsy
Primary: Change From Baseline in Maintenance of Wakefulness Test (MWT) Score at Day 21 of Stable Dosing Phase — 6.30; 5.81; 1.29; 1.10 minutes — p=0.418
Aspergillosis, Aspergilloma
Primary: Area Under the Plasma Concentration-time Profile From Time Zero to Twelve Hours at Steady-State (AUC12,ss) Following IV Administration — 51.92; 83.39; 17.27 μg*h/mL
Open-Angle Glaucoma · Ocular Hypertension
Primary: Mean Change in Intraocular Pressure (IOP) at 12 Weeks From Prior Therapy (Baseline) — 17.0; -1.16 millimeters mercury (mmHg)
Idiopathic Parkinson's Disease
Primary: Change From Baseline to the End of Maintenance in Total Nonmotor Symptoms Scale (NMSS) Score — -19.1; -23.1 scores on a scale — p=0.147
Diphtheria · Tetanus · Pertussis
Primary: Equivalence of Seroprotection Against Vaccine Antigens in Study Participants After Vaccination With Either One of the Batches of DTaP-IPV-HB-PRP~T or Infanrix Hexa™…
Left Ventricular Diastolic Dysfunction
Primary: Change in Urinary Sodium Excretion in Response to Saline Load — 381.6; -10.5 mEq/minute — p=<0.001
Osteoarthritis
Primary: Safety of Diclofenac 35 mg Capsules as Assessed by the Incidence of Adverse Events From Baseline to Week 52 or Early Termination — 451; 41; 42 participants
Diabetes · Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c (Glycosylated Haemoglobin) — -1.32; -1.31 percentage of glycosylated haemoglobin
Leukemia, Acute Myelogenous (AML) · Leukemia, Acute Lymphocytic (ALL) · Leukemia, Chronic Myelogenous (CML)
Primary: Toxicity — 5 participants
Saccadic Eye Movements
Primary: Dynamic Eye Movement Measures — -25; -115; -90; 10 (degrees/second)
Solid Tumors · Advanced Cancer
Primary: Number of Participants With Adverse Events in Sequential Cohort Dose Escalation Study of AMG 531 Following Chemotherapy — 0; 0; 1; 4 participants
Depression
Primary: Medication Adherence, as Measured by Electronic Pill Container — 58.76; 34.7 Percentage of Days — p=<.05
Airway Reflexes, Protective · Recovery After Neuromuscular Block · Anesthetic Recovery
Primary: Recovery of Ability to Swallow After Neostigmine/Glycopyrrolate Antagonism of Rocuronium Paralysis. — 16; 25; 10; 6 participants — p=0.11
Rheumatoid Arthritis (RA)
Primary: Dose-Normalized AUC[0-Inf] for MTX — 109.47; 140.84; 136.45 ng*hr/mL/mg
Diabetes · Depression
Primary: Change in PHQ-9 (Patient Health Questionnaire-9)Scores — 5.14; 7.03 scores on a scale